Enabling Healthier Communities is ingrained into CSL’s purpose. Meeting the needs of people, patients and communities is the reason CSL exists. From developing new, innovative therapies for diseases to enabling greater access to life-saving vaccines, protecting the health and wellbeing of patients and communities around the world is at the centre of CSL’s purpose as a business. CSL has identified focus areas where it can have the most positive impact and help to create healthier communities, these include: Access and affordability – advance equitable access CSL’s medicines and vaccines Patient experience – elevate patient experience in drug development by embedding patient insights and lived experience Donor experience – create best-in-class donor experience in partnership with donors and communities, by continuously innovating the donation process, supporting donors’ holistic well-being, and investing in the health equity of donor communities. Equitable access to CSL’s products The people and science of CSL save lives. CSL develops and delivers innovative medicines that help people with serious and life-threatening conditions live full lives, and protects the health of communities around the world. Through continued supply and development of innovative products, CSL enables greater access to life-saving vaccines, iron therapies, plasma and protein-based therapies. CSL’s global network enables extending the reach of CSL’s therapies and vaccines to help advance equitable access across vulnerable populations, while sharing expertise to help build capabilities where they are needed. CSL is committed to working with governments, health insurance payers, and other stakeholders to design new payment and access solutions that reflect value and meet the needs of individual patients and healthcare systems. To enable patients to benefit from CSL’s therapies as quickly as possible, CSL works with key stakeholders supporting timely and appropriate market entry and access. CSL values ongoing dialogue with policy makers, advocacy groups, and other stakeholders to understand and respond to their needs and expectations. CSL recognises the importance of collaboration and is also a supporter of, and provides both monetary and product donations to, various patient assistance programs and supports advocacy efforts that improve access to care and affordability across the world. US$16.5m* supporting product access across the world US$14.1b economic value distributed over the reporting period in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions* Community contributions Guided by CSL’s Community Contributions Policy and investment focus areas of support, in FY2025, CSL contributed US$35.4 million to support global community efforts where we operate. 68% to patient communities 29% to innovation and science 3% to local communities • Enhancing quality of life for patients with the conditions our therapies treat • Improving access to our biological medicines • Advancing knowledge in medical and scientific communities • Fostering the next generation of medical researchers • Supporting community efforts where we live and work • Supporting communities in times of emergency FOCUS AREA^ SUB FOCUS AREAS Healthier Communities * Limited assurance by Deloitte. 27 CSL Limited Annual Report 2024/25
RkJQdWJsaXNoZXIy MjE2NDg3